Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maitake mushroom extract compound is a botanical preparation derived from the *Grifola frondosa* fungus, specifically investigated by the Chinese PLA General Hospital as a clinical nutrition intervention for patients with lung and breast cancers. The extract is characterized by its high concentration of bioactive beta-glucans, particularly 1,3-beta-glucan and 1,6-beta-glucan. These compounds function as biological response modifiers that stimulate the innate immune system by binding to pattern recognition receptors like Dectin-1 on macrophages and natural killer (NK) cells. In clinical settings, it is evaluated for its ability to enhance immune function and mitigate the immunosuppressive effects of chemotherapy and radiation therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maitake mushroom extract compound.